Rein Daniel T, Volkmer Anne Kathrin, Volkmer Jens, Beyer Ines M, Janni Wolfgang, Fleisch Markus C, Welter Anne Kathrin, Bauerschlag Dirk, Schöndorf Thomas, Breidenbach Martina
Department of Obstetrics and Gynaecology, University of Düsseldorf Medical Centre, D-40225 Düsseldorf, Germany.
Oncol Lett. 2012 Mar;3(3):530-534. doi: 10.3892/ol.2012.553. Epub 2012 Jan 3.
Ovarian cancer patients often suffer from malignant ascites and pleural effusion. Apart from worsening the outcome, this condition frequently impairs the quality of life in patients who are already distressed by ovarian cancer. This study investigated whether single intraperitoneal administration of the anti-VEGF antibody bevacizumab is capable of reducing the ascites-related body surface and prolonging survival. The study was performed in an orthotopic murine model of peritoneal disseminated platin-resistant ovarian cancer. Mice were treated with bevacizumab and/or paclitaxel or buffer (control). Reduction of body surface and increased survival rates were assessed as therapeutic success. Survival of mice in all treatment groups was significantly enhanced when compared to the non-treatment control group. The combination of paclitaxel plus bevacizumab significantly improved body surface as well as overall survival in comparison to a treatment with only one of the drugs. Treatment of malignant effusion with a single dose of bevacizumab as an intraperitoneal application, with or without cytostatic co-medication, may be a powerful alternative to systemic treatment.
卵巢癌患者常伴有恶性腹水和胸腔积液。除了使病情恶化外，这种情况还经常损害已因卵巢癌而痛苦的患者的生活质量。本研究调查了腹腔单次注射抗血管内皮生长因子（VEGF）抗体贝伐单抗是否能够减少与腹水相关的体表面积并延长生存期。该研究在铂耐药性卵巢癌腹膜播散的原位小鼠模型中进行。小鼠接受贝伐单抗和/或紫杉醇或缓冲液（对照）治疗。将体表面积的减少和生存率的提高评估为治疗成功。与未治疗的对照组相比，所有治疗组小鼠的生存期均显著延长。与仅使用一种药物治疗相比，紫杉醇加贝伐单抗的联合治疗显著改善了体表面积和总生存期。单剂量贝伐单抗腹腔内应用治疗恶性积液，无论是否联合使用细胞抑制剂，都可能是全身治疗的有力替代方案。
